Skip to main content

Table 5 Univariate and multivariate analysis of clinicopathologic factors for OS

From: Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study

Variables Univariate Multivariate
HR 95% CI P HR 95% CI P
Age (years)
 < 60 yr 1.000    1.000   
 ≥ 60 yr 1.540 1.107–2.141 0.010 1.418 1.000–2.011 0.050
Sex
 Male 1.000      
 Female 1.105 0.777–1.571 0.577    
BMI
 < 23 1.000      
 ≥ 23 1.020 0.735–1.417 0.905    
Surgical approach
 Traditional open 1.000      
 Laparoscopic-assisted 0.918 0.640–1.318 0.644    0.769
Intraoperative blood loss
 ≤ 100 ml 1.000    1.000   
 >100 ml 1.740 1.191–2.527 0.004 1.780 1.211–2.617 0.003
Postoperative complications
 Negative 1.000      
 Positive 1.551 1.001–2.404 0.050    0.729
Tumor length/diameter
 < 5 cm 1.000      
 ≥ 5 cm 1.738 1.254–2.408 0.001    0.288
Histological type
 HD/MD/M-LD 1.000      
 LD/MA/SRC 1.489 1.072–2.068 0.018    0.094
Vascular tumor embolus
 Negative 1.000      
 Positive 1.956 1.372–2.789 < 0.001    0.626
Depth of Invasion (T)
 T1/T2/T3 1.000      
 T4a/T4b 2.133 1.525–2.983 < 0.001    0.526
Lymph node metastasis (N)
 N0/N1 1.000      
 N2/N3 3.247 2.227–4.736 < 0.001    0.336
TNM    < 0.001    < 0.001
 IIA 1.000      
 IIB 2.905 1.263–6.680 0.012 2.667 1.158–6.142 0.021
 IIIA 4.375 2.067–9.259 < 0.001 4.579 2.162–9.697 < 0.001
 IIIB 8.092 3.817–17.156 < 0.001 9.092 4.277–19.327 < 0.001
 IIIC 14.987 6.776–33.145 < 0.001 16.948 7.627–37.662 < 0.001
Serum CEA level
 ≤ 5 ng/ml 1.000      
 >5 ng/ml 1.183 0.802–1.744 0.396    
Serum CA199 level
 ≤ 37 U/ml 1.000      
 >37 U/ml 1.333 1.082–1.644 0.007    0.981
Adjuvant chemotherapy cycles    < 0.001    < 0.001
 Not received (A) 1.000    1.000   
 7–8 or 10–12 cycles (B) 0.459 0.301–0.699 < 0.001 0.386 0.247–0.604 < 0.001
 4–6 or 6–9 cycles (C) 0.504 0.314–0.807 0.004 0.493 0.304–0.800 0.004
 ≤ 3 or 5 cycles (D) 1.032 0.638–1.670 0.897 0.870 0.530–1.427 0.580
  1. Note: HD/MD/M-LD High/Median/Median-Low differentiation adenocarcinoma, LD/MA/SRC Low differentiation adenocarcinoma/Mucinous adeno-carcinoma/ Signet-ring cell carcinoma, HR Hazard ratio, CI Confidence interval. P < 0.05, statistically significant